NASDAQ:LVTX - Lava Therapeutics B.V. Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $23.00
  • Forecasted Upside: 237.74 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$6.81
▼ -0.34 (-4.76%)

This chart shows the closing price for LVTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Lava Therapeutics B.V. Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LVTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LVTX

Analyst Price Target is $23.00
▲ +237.74% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Lava Therapeutics B.V. in the last 3 months. The average price target is $23.00, with a high forecast of $24.00 and a low forecast of $22.00. The average price target represents a 237.74% upside from the last price of $6.81.

This chart shows the closing price for LVTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 polled investment analysts is to buy stock in Lava Therapeutics B.V..

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/1/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/30/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/26/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/25/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/23/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/23/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/17/2021SVB LeerinkLower Price TargetOutperform$26.00 ➝ $24.00Low
4/19/2021JPMorgan Chase & Co.Initiated CoverageOverweight$22.00Low
4/19/2021Jefferies Financial GroupInitiated CoverageBuy$23.00Low
4/19/2021SVB LeerinkInitiated CoverageOutperform$26.00Low
(Data available from 10/23/2016 forward)

News Sentiment Rating

-0.80 (Sell)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/27/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/26/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/26/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/25/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/25/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/24/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/23/2021
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
10/23/2021

Current Sentiment

  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Lava Therapeutics B.V. logo
Lava Therapeutics B.V., a biotechnology company, engages in developing a portfolio of bispecific gamma-delta T cell engagers (gamma-delta bsTCEs) for the treatment of solid tumors and hematologic malignancies based on its platform. Its lead product candidate, LAVA-051, is advancing toward a Phase 1/2a clinical trial for the treatment of CD1d-expressing hematologic cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia. The company also develops its gamma-delta bsTCEs in solid tumors, which targets prostate-specific membrane antigen for the treatment of prostate cancer. Lava Therapeutics B.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of potential product candidates. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.
Read More

Today's Range

Now: $6.81
Low: $6.79
High: $7.18

50 Day Range

MA: $6.30
Low: $5.50
High: $7.63

52 Week Range

Now: $6.81
Low: $5.50
High: $17.20

Volume

12,446 shs

Average Volume

96,782 shs

Market Capitalization

$172.65 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Lava Therapeutics B.V.?

The following sell-side analysts have issued research reports on Lava Therapeutics B.V. in the last twelve months: Jefferies Financial Group Inc., JPMorgan Chase & Co., SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for LVTX.

What is the current price target for Lava Therapeutics B.V.?

3 Wall Street analysts have set twelve-month price targets for Lava Therapeutics B.V. in the last year. Their average twelve-month price target is $23.00, suggesting a possible upside of 237.7%. SVB Leerink LLC has the highest price target set, predicting LVTX will reach $24.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $22.00 for Lava Therapeutics B.V. in the next year.
View the latest price targets for LVTX.

What is the current consensus analyst rating for Lava Therapeutics B.V.?

Lava Therapeutics B.V. currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe LVTX will outperform the market and that investors should add to their positions of Lava Therapeutics B.V..
View the latest ratings for LVTX.